Immunomedics Inc - Product Pipeline Review

Global Markets Direct’s, ‘Immunomedics Inc - Product Pipeline Review - 2016’, provides an overview of the Immunomedics Inc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Immunomedics Inc

The report provides overview of Immunomedics Inc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Immunomedics Inc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Immunomedics Inc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Immunomedics Inc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Immunomedics Inc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Immunomedics Inc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Immunomedics Inc Snapshot 7

Immunomedics Inc Overview 7

Key Facts ...

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Immunomedics Inc Snapshot 7

Immunomedics Inc Overview 7

Key Facts 7

Immunomedics Inc - Research and Development Overview 8

Key Therapeutic Areas 8

Immunomedics Inc - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Immunomedics Inc - Pipeline Products Glance 17

Immunomedics Inc - Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Immunomedics Inc - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Immunomedics Inc - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Immunomedics Inc - Unknown Stage Pipeline Products 22

Unknown Products/Combination Treatment Modalities 22

Immunomedics Inc - Drug Profiles 23

14-3s - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

15-3s - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

19-3s - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

1R-15-15 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

1R-2b - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

1R-3s - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

1R-E1-E1 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

20-3s - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

202-b - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

C2-3s - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

E1-3s - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

epratuzumab - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Hex-hR1 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

IMMU-110 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

IMMU-114 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

IMMU-140 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

labetuzumab govitecan - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

M1-3s - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

milatuzumab - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Monoclonal Antibody Conjugate to Target CD19 for B-Cell Hematologic Malignancies - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Monoclonal Antibody Conjugate to Target CEACAM6 for Colon Cancer and Breast Cancer - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Monocloncal Antibody to Target CD-19 for Oncology - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

sacituzumab - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

TF-12 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

TF-2 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

veltuzumab - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

yttrium Y 90 epratuzumab tetraxetan - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Immunomedics Inc - Pipeline Analysis 75

Immunomedics Inc - Pipeline Products by Target 75

Immunomedics Inc - Pipeline Products by Route of Administration 77

Immunomedics Inc - Pipeline Products by Molecule Type 78

Immunomedics Inc - Pipeline Products by Mechanism of Action 79

Immunomedics Inc - Dormant Projects 82

Immunomedics Inc - Discontinued Pipeline Products 83

Discontinued Pipeline Product Profiles 83

clivatuzumab tetraxetan 83

epratuzumab 83

ImmuRAIT-LL2 83

veltuzumab 83

Immunomedics Inc - Company Statement 85

Immunomedics Inc - Locations And Subsidiaries 87

Head Office 87

Other Locations & Subsidiaries 87

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89

List of Tables

List of Tables

Immunomedics Inc, Key Facts 7

Immunomedics Inc - Pipeline by Indication, 2016 9

Immunomedics Inc - Pipeline by Stage of Development, 2016 13

Immunomedics ...

List of Tables

Immunomedics Inc, Key Facts 7

Immunomedics Inc - Pipeline by Indication, 2016 9

Immunomedics Inc - Pipeline by Stage of Development, 2016 13

Immunomedics Inc - Monotherapy Products in Pipeline, 2016 14

Immunomedics Inc - Partnered Products in Pipeline, 2016 15

Immunomedics Inc - Partnered Products/ Combination Treatment Modalities, 2016 16

Immunomedics Inc - Phase III, 2016 17

Immunomedics Inc - Phase II, 2016 18

Immunomedics Inc - Phase I, 2016 19

Immunomedics Inc - Preclinical, 2016 20

Immunomedics Inc - Discovery, 2016 21

Immunomedics Inc - Unknown, 2016 22

Immunomedics Inc - Pipeline by Target, 2016 76

Immunomedics Inc - Pipeline by Route of Administration, 2016 77

Immunomedics Inc - Pipeline by Molecule Type, 2016 78

Immunomedics Inc - Pipeline Products by Mechanism of Action, 2016 80

Immunomedics Inc - Dormant Developmental Projects,2016 82

Immunomedics Inc - Discontinued Pipeline Products, 2016 83

Immunomedics Inc, Other Locations 87

Immunomedics Inc, Subsidiaries 87

List of Figures

List of Figures

Immunomedics Inc - Pipeline by Top 10 Indication, 2016 9

Immunomedics Inc - Pipeline by Stage of Development, 2016 13

Immunomedics Inc - Monotherapy Products ...

List of Figures

Immunomedics Inc - Pipeline by Top 10 Indication, 2016 9

Immunomedics Inc - Pipeline by Stage of Development, 2016 13

Immunomedics Inc - Monotherapy Products in Pipeline, 2016 14

Immunomedics Inc - Pipeline by Top 10 Target, 2016 75

Immunomedics Inc - Pipeline by Route of Administration, 2016 77

Immunomedics Inc - Pipeline by Molecule Type, 2016 78

Immunomedics Inc - Pipeline Products by Top 10 Mechanism of Action, 2016 79

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports